{"id":"W3163043692","doi":"10.1016/j.jacc.2021.05.003","title":"Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial","year":2021,"lang":"en","type":"article","venue":"Journal of the American College of Cardiology","topic":"Peripheral Artery Disease Management","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"ca_institutions":"Population Health Research Institute; McMaster University; Hamilton Health Sciences","funders":"Janssen Pharmaceuticals; Bayer Corporation; Bayer Canada; American Heart Association","keywords":"Medicine; Rivaroxaban; Clinical endpoint; Revascularization; Aspirin; Stroke (engine); Cardiology; Internal medicine; Population; Vascular disease; Myocardial infarction; Randomized controlled trial; Surgery; Anesthesia; Warfarin; Atrial fibrillation","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001760873,0.0007252448,0.001560668,0.0002317085,0.0001699649,0.0009922113,0.0004553812,0.0007336358,0.002405219],"category_scores_gemma":[0.00170835,0.0001925417,0.002239494,0.0002801402,0.0004145603,0.0004434682,0.0003670135,0.001752272,0.000299437],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003505012,"about_ca_system_score_gemma":0.0004118793,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002751136,"about_ca_topic_score_gemma":0.0005329576,"domain_scores_codex":[0.9993622,0.00037701,0.00003610623,0.00008665765,0.00005631397,0.00008177085],"domain_scores_gemma":[0.9994381,0.0001701593,0.0001738084,0.00006059285,0.00002915089,0.0001281461],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8926421,0.003870045,0.008975178,0.002167624,0.006944485,0.0001941745,0.0001134404,0.00224141,0.003868813,0.0007276914,0.006004935,0.07225008],"study_design_scores_gemma":[0.8703724,0.06587522,0.0487479,0.0003870601,0.004117177,0.0004444894,0.00008399458,0.002215635,0.000998863,0.001858845,0.004850717,0.00004779618],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9749458,0.01695824,0.0007420699,0.001088692,0.000490832,0.0006293083,0.00103608,0.0001509724,0.003957985],"genre_scores_gemma":[0.9908178,0.003028034,0.0008389939,0.001034161,0.0004243033,0.0008790519,0.001326646,0.00001871264,0.001632367],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002405219,"threshold_uncertainty_score":0.00931251,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006755752166840405,"score_gpt":0.2430622178150727,"score_spread":0.2363064656482323,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}